| The question of heart failure in ONTARGET and TRANSCEND: implications for clinical practice. | |
| | |
MedLine Citation:
|
PMID: 19491621 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
In patients with arterial hypertension and/or high cardiovascular risk, including patients with diabetes, chronic ischemic heart disease and kidney disease, the risk of heart failure decreases with blood pressure reduction and the use of drugs that inhibit the renin-angiotensin system (RAS) [angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs)]. The heart failure incidence seen in ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) and Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) is in line with this observation. In ONTARGET, telmisartan and ramipril were equally effective in heart failure prevention and with the same blood pressure reduction. The low event rate, including the low incidence of heart failure in TRANSCEND with the greater use of diuretics in the placebo arm, may help to explain the absence of significant differences between telmisartan and placebo. |
| | |
Authors:
|
Jos? R Gonz?lez-Juanatey |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Journal of hypertension. Supplement : official journal of the International Society of Hypertension Volume: 27 ISSN: 0952-1178 ISO Abbreviation: J Hypertens Suppl Publication Date: 2009 Jun |
Date Detail:
|
Created Date: 2009-06-03 Completed Date: 2009-09-01 Revised Date: 2010-05-18 |
Medline Journal Info:
|
Nlm Unique ID: 8501422 Medline TA: J Hypertens Suppl Country: England |
Other Details:
|
Languages: eng Pagination: S32-5 Citation Subset: IM |
Affiliation:
|
Cardiology Department, Hospital Cl?nico Universitario, Santiago de Compostela, Spain. jose.ramon.gonzalez.juanatey@sergas.es |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antihypertensive Agents
/
pharmacology,
therapeutic use Heart Failure / complications, drug therapy, physiopathology* Humans Receptors, Angiotensin / antagonists & inhibitors Renin-Angiotensin System / drug effects |
| Chemical | |
Reg. No./Substance:
|
0/Antihypertensive Agents; 0/Receptors, Angiotensin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Benefits of the RAS blockade: clinical evidence before the ONTARGET study.
Next Document: ONTARGET, TRANSCEND, and PRoFESS: new-onset diabetes, atrial fibrillation, and left ventricular hype...